SpyGlass Pharma, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Patrick Mooney (CEO) and Jean-Frédéric Viret (CFO) issued standard Sarbanes-Oxley 302 and 906 certifications on August 6, 2026, attesting that the Q2 2026 10-Q fairly presents financial condition and that disclosure controls are effective. The certifications contain no disclosure of material weaknesses, significant deficiencies, or fraud.
Why this rating
Routine SOX compliance certification; no substantive business developments disclosed.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.